• Francisco Gudiol, José María Aguado, Alvaro Pascual, Miquel Pujol, Benito Almirante, José María Miró, Emilia Cercenado, María de Los Angeles Domínguez, Alex Soriano, Jesús Rodríguez-Baño, Jordi Vallés, Mercedes Palomar, Pilar Tornos, Emilio Bouza, and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.
• Servicio de Enfermedades Infecciosas, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, España.
• Enferm. Infecc. Microbiol. Clin. 2009 Feb 1; 27 (2): 105-15.

AbstractBacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.

40 keywords...

hide…